Private radiology group Prenuvo raised $120 million in Series B funding in 2024.
Co-led by Forerunner Ventures, Left Lane Capital, and existing investor Felicis, the funding will accelerate Prenuvo’s augmentation of its core whole-body MRI screening with additional modalities and analyses of the human body, according to the company.
The fundraising disclosure complements Prenuvo securing U.S. Food and Drug Administration (FDA) clearance for its AI-powered body composition report. The report can now provide actionable and quantitative data on visceral fat, subcutaneous fat, liver fat, muscle volumes, and the volume of vital abdominal organs; data on brain function, cognitive health, and early indicators of neurodegenerative conditions; and blood biomarker testing insights related to metabolic, cardiovascular, hormonal, and immune health, according to Prenuvo.
The new body screening capabilities will launch in a bundled offering, the company said.